ORIC-101
Multiple Solid Tumors
Phase 1bActive
Key Facts
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biotech with a mission to overcome therapeutic resistance in cancer, a primary cause of treatment failure. The company has successfully raised over $900 million, advanced four programs into clinical trials, and is progressing key assets like ORIC-114 and rinzimetostat (ORIC-944) in late-phase 1b/2 studies. Its strategy centers on a proprietary resistance platform to develop combination therapies that extend the efficacy of standard-of-care treatments, positioning it as a potential partner of choice in the oncology landscape.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Abexinostat + Pembrolizumab | Xynomic Pharmaceuticals | Phase 1b |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| UNO (Ultrahigh NO) | Beyond Air | Phase 1/2 |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| Metastasis Companion Diagnostic | Mestastop Solutions | Prospective Clinical Trials |
| Anti-metastasis Drug Discovery | Mestastop Solutions | Preclinical/Discovery |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |